























to the editor: 
 





port that serial renal biopsies in recipients of kid-
ney and pancreas transplants who were given cal-
cineurin inhibitors showed that chronic rejection
was rare but that, over time, these drugs led to irre-
versible lesions. The authors conclude that cal-
cineurin inhibitors are unsuitable for long-term im-
munosuppression.
The authors should be congratulated for their in-
formative contribution, but their conclusions may
be challenged. With a regimen based on calcineurin
inhibitors, Nankivell et al. report that the survival
rate for kidney grafts, with data censored for patients
who died, was 95.2 percent at 10 years. I wonder
whether immunosuppressive regimens without cal-
cineurin inhibitors would have prevented chronic
rejection, which represented by far the most com-
mon cause of late graft failure before the introduc-
tion of calcineurin inhibitors. On the other hand, the
nephrotoxicity of calcineurin inhibitors does not
necessarily lead to the failure of kidney grafts over
time. On the basis of our own cumulative experience
with cyclosporine, my colleagues and I reported a
graft half-life, with data censored for patients who
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to the editor: 
 
Nankivell et al. analyzed the delete-
rious effect of ischemia on graft outcome at one
year. They found an increased incidence of chronic
allograft nephropathy among patients with acute tu-
bular necrosis, predominantly with a new onset of
tubulointerstitial damage. We recently assessed the
distinct contributions of alloreactivity and cold is-





 Our findings suggest that although
immune activation plays the most critical role, is-
chemia added to the allogeneic background turns
into a strong inflammatory insult that accelerates
the involved cellular mechanisms, leading to se-
vere tubulointerstitial damage. The usual immuno-
suppressive schedule used in this well-established
model of chronic allograft nephropathy could not
control the early immune inflammatory response.
These findings suggest that the introduction of new
drugs to interfere with these initial mechanisms
might be an exciting strategy to explore. In fact,
there is some evidence of a promising beneficial
effect of antiinflammatory or immunomodulatory
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plantation inflammatory T-cell–mediated cellular
changes associated with renal ischemic injury to
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to the editor: 
 
Chronic allograft nephropathy has
previously been suggested to cause graft loss in 30
to 40 percent of cases in which the allograft failed





er, calcineurin-inhibitor toxicity was implicated in
less than 10 percent of cases. In contrast, Nankivell
et al. report that 10 years after transplantation,
100 percent of patients had calcineurin-inhibitor
nephrotoxicity, and the authors therefore suggest
calcineurin-inhibitor–free immunosuppression for
long-term treatment. In view of the major implica-
tions for the treatment of chronic allograft ne-
phropathy, the sensitivity and specificity of the his-
topathological diagnosis of calcineurin-inhibitor
nephrotoxicity, as well as interobserver variation,
should be provided. Previous studies have already
shown a very high rate of interobserver variation in
the interpretation of findings on renal-transplant





 Furthermore, since whole-blood
concentrations of calcineurin inhibitors, and pre-
sumably also the type of calcineurin inhibitor used,
affect nephrotoxicity, trough levels of cyclosporine
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the authors reply: 
 
We do not propose the com-
plete abandonment of calcineurin inhibitors in the
absence of alternative approaches to immunosup-
pression that have been proved effective. As noted
by Dr. Ponticelli, our excellent 10-year rate of graft
survival, with data censored for patients who died,
was facilitated by the use of calcineurin inhibitors,
agents that probably alter the histologic pattern of
transplanted kidneys. However, any projected im-
provement in graft half-life must be contrasted with
actual graft-survival curves, which still show a pro-





 Whether calcineurin inhibitors can
be administered at an effective and safe dose is
problematic. Our data indicated that a dose of 5 mg
of cyclosporine per kilogram of body weight per day
or a higher dose led to progressive arteriolar hyali-
nosis in pairs of specimens from sequential biop-
sies, suggesting a threshold dose for cyclosporine
nephrotoxicity in this population (but not necessar-
ily in individual patients). This dose is remarkably
similar to the widely cited optimal cyclosporine dose





 indicating an overlap of the
nephrotoxic and therapeutic ranges. Hence, we re-
affirm our conviction that cyclosporine is unsuitable
for long-term therapy in a broad population of kid-
ney-transplant recipients.
We agree with Dr. Pietrzyk and colleagues that
interobserver variation occurs in the assessment of
renal-transplant biopsy specimens, particularly with
acute rejection, which, with the use of the Banff
schema, hinges on the finding of relatively scarce tu-
bulitis. In contrast, the changes of chronic allograft
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nephropathy are relatively easy to recognize and
there is correspondingly better agreement between
pathologists on these changes. Our interobserver
kappa statistics for chronic allograft nephropathy,
calcineurin nephrotoxicity, and subclinical rejection
were 0.61, 0.48, and 0.76, respectively, and the in-
traobserver kappa statistics were 0.93, 0.83, and
0.80, respectively. Variation was easily compensated
for by the large numbers of biopsies. The specificity
and sensitivity for the diagnosis of chronic allograft
nephropathy were not calculated, since histologic
examination itself is the gold standard. The mean
(±SD) cyclosporine dose and trough levels at 1, 5,
and 10 years were 5.1±1.5, 4.7±1.5, and 4.1±1.0 mg
per kilogram per day and 221±115, 178±102, and
121±51 ng per milliliter, respectively. The one-year
tacrolimus dose and trough levels were 0.12±0.06
mg per kilogram per day and 12.4±4.6 ng per mil-
liliter, respectively. Substantial calcineurin-inhibitor
nephrotoxicity still occurred with conventional dos-
es and trough levels.
Our study showed an independent effect of both
ischemic injury and acute rejection in contributing
to tubular damage, results that were similar to the
experimental histologic findings of Dr. Torras and
colleagues, but we cannot discriminate between an
additive and a synergistic mode of action. The great-
est burden of tubulointerstitial damage occurred
within three months after transplantation and was
reduced by tacrolimus and mycophenolate therapy.
Hence, controlling early immune-mediated injury
and ischemia–reperfusion damage remains the best
strategy for preserving functional nephrons.
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Surgeon Volume and Operative Mortality
 
to the editor: 
 




demonstrated that an individual surgeon’s volume
was a better predictor of lower mortality for certain





 interpreted these data
to conclude that patients and health plans should
preferentially choose high-volume surgeons for cer-
tain procedures or should at least avoid low-volume
surgeons.
As a surgeon and surgical educator, I do not
doubt the validity of the data reported by Birkmeyer
et al., nor do I disagree with Kizer’s recommenda-
tions. However, we must remember that every high-
volume surgeon began practice as a low-volume sur-
geon, who subjected some number of patients to the
increased risk associated with undergoing an oper-
ation performed by a low-volume surgeon. So, as
Kizer states, we are faced with an ethical conun-
drum. An educated, informed patient with the
means to choose will prefer a high-volume surgeon.
But on whom will the low-volume surgeons operate
in order to become high-volume surgeons? Patients
of modest knowledge and means? And if there is no
opportunity to practice on less choosy patients,
where will future high-volume surgeons come from?
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to the editor: 
 
Birkmeyer et al. infer from Medicare
statistics that a higher surgical-case volume ac-
counts for improved outcomes of various surgical
procedures. Is it possible that the cart has been
placed before the horse?
From my view as a referring physician, a some-
what different perspective may be obtained. There is
a well-developed grassroots information network at
every institution, which provides dynamic informa-
tion on surgical skills, experience, and unexpected
outcomes. This network drives referrals to surgeons
with good outcomes and is the basis of the relation-
ship between outcome and volume. Birkmeyer et al.
have not established that volume begets quality,
rather than the other way around.
Gifted, high-volume surgeons must at some
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